acquired
Stage
3
Investors
About
Inflazome develops orally available small molecule inhibitors targeting the NLRP3 inflammasome to treat age-related and orphan inflammatory diseases characterized by harmful inflammation.
Explore Inflazome's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.